Effect of dexamethason on the incidence of detubation failure in children.

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON28763

Source NTR

Brief title N/A

Health condition

Mechanically ventilated children.

Sponsors and support

Primary sponsor: Department of pediatrics
VU University Medical Center
Postbus 7057
1007 MB Amsterdam
Source(s) of monetary or material Support: N/A

Intervention

Outcome measures

Primary outcome

Detubation failure.

Secondary outcome

1. Use of other therapies to reduce upper airway obstruction (epinephrin, beclomethasone);

- 2. Croup score;
- 3. Supplemental oxygen;

4. Adverse effects of dexamethason: hypertension, Gatro-intestinal tract bleeding, hyperglycaemia.

Study description

Background summary

Upper airway obstrection is frequently seen (30%) after detubation in children at risk (4 weeks-4years, and prolonged intabation > 24 hours). There is often a need for reintubation (5%). Dexamethason may reduce the the frequency of upper airway obstruction and the need for reintubation. This has been studied earlier, however there is a lack of properly designed studies.

Study objective

Dexamethason reduces the rate of detubation failure in children at risk.

Study design

N/A

Intervention

Dexamethason 6 x 0,5 mg/kg i.v. à 6 uur (max 10 mg dose) first dose 6 - 12 hours prior to detubation.

Placebo: Saline (NaCl 0,9%).

Contacts

Public

VU University Medical Center, Department of Pediatric Intensive Care, P.O. Box 7057

2 - Effect of dexamethason on the incidence of detubation failure in children. 7-05-2025

M. Heerde, van Amsterdam 1007 MB The Netherlands +31 (0)20 4444426 / +31 (0)20 4443000 **Scientific** VU University Medical Center, Department of Pediatric Intensive Care, P.O. Box 7057 M. Heerde, van Amsterdam 1007 MB The Netherlands +31 (0)20 4444426 / +31 (0)20 4443000

Eligibility criteria

Inclusion criteria

- 1. Age 4 weeks 4 years;
- 2. Intubated > 24 hours;
- 3. Informed consent.

Exclusion criteria

- 1. Known with one of the following diseases:
- a. peptic ulcus;
- b. diabetes mellitus;
- c. osteoporosis;
- d. adrenal insufficiency;
- e. hypertension;
- f. systemic yeast infection;
- g. tuberculosis;
- h. sepsis;

- 2. Glucocorticoid use the week before detubation;
- 3. Intubation for laryngotracheal infection;
- 4. Mechanical ventilation for upper airway obstruction;
- 5. Down syndrome.

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NI

Recruitment status:	Recruitment stopped	
Start date (anticipated):	01-01-2004	
Enrollment:	157	
Туре:	Actual	

Ethics review

Positive opinion	
Date:	
Application type:	

24-08-2005 First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL110
NTR-old	NTR141
Other	: N/A
ISRCTN	ISRCTN54608329

Study results

Summary results

N/A